¼¼°èÀÇ ¼Ò¾Æ¿ë ÀǾàǰ ½ÃÀå º¸°í¼­(2025³â)
Pediatric Drugs Global Market Report 2025
»óǰÄÚµå : 1815891
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 250 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,362,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 9,196,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 12,031,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼Ò¾Æ¿ë ÀǾàǰ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ ±Þ¼ºÀåÇÒ °ÍÀ¸·Î Àü¸ÁµË´Ï´Ù. 2029³â¿¡´Â CAGR 14.5%¸¦ ³ªÅ¸³» 3,085¾ï 7,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº ¼Ò¾Æ Àα¸ Áõ°¡, ¼Ò¾Æ Á¤½Å À§»ý ¹®Á¦ÀÇ À¯º´·ü Áõ°¡, ¸¸¼º ÁúȯÀ» ¾Î´Â ¼Ò¾Æ ¼ö Áõ°¡, ¼Ò¾Æ ¹é½Å Á¢Á¾·ü Áõ°¡, ¼Ò¾Æ Á¤½Å À§»ý ¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇÑ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ Áß ÁÖ¿ä µ¿ÇâÀ¸·Î´Â ¼Ò¾Æ ÀÇ·á °³ÀÎÈ­, ¼Ò¾Æ ¾à¹° Àü´Þ ±â¼ú ÅëÇÕ, ¿ø°Ý ÀÇ·á ¹× µðÁöÅÐ °Ç°­ ¼Ö·ç¼Ç, ¼Ò¾Æ ÀÓ»ó½ÃÇè °­È­, ¼Ò¾Æ°ú ÀÇ»ç¿Í ¾à»ç °£ÀÇ Çù·Â µîÀÌ ÀÖ½À´Ï´Ù.

ÇâÈÄ 5³â°£ÀÇ ¼ºÀå·ü 14.5%¶ó°í ÇÏ´Â ¿¹ÃøÀº ÀÌ ½ÃÀåÀÇ Àüȸ ¿¹ÃøÀ¸·ÎºÎÅÍ 0.4%ÀÇ ¼ÒÆøÀÇ °¨¼Ò¸¦ ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÀÌ °¨¼Ò´Â ÁÖ·Î ¹Ì±¹°ú ´Ù¸¥ ±¹°¡ °£ÀÇ °ü¼¼ÀÇ ¿µÇâ ¶§¹®ÀÔ´Ï´Ù. ¹«¿ª ¸¶ÂûÀº ½º¿þµ§°ú ³×´ú¶õµå¿¡¼­ »ý»êµÇ´Â Ư¼ö ¼Ò¾Æ¿ë Á¦ÇüÀÇ °¡°ÝÀ» ´Ã¸®°í ¼Ò¾Æ ¸¸¼º ÁúȯÀÇ Ä¡·á Áö¿¬°ú ¼Ò¾Æ ÀÇ·áºñÀÇ »ó½ÂÀ» ÃÊ·¡ÇÏ¿© ¹Ì±¹ ¼Ò¾Æ º´¿ø¿¡ ÁöÀåÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ »óÈ£°ü¼¼³ª ¹«¿ª¸¶Âû¡¤Á¦ÇÑÀÇ °ÝÈ­¿¡ ÀÇÇÑ ¼¼°è°æÁ¦¡¤¹«¿ª¿¡ ´ëÇÑ ¾Ç¿µÇâ¿¡ ÀÇÇØ ±× ¿µÇâÀº º¸´Ù ±¤¹üÀ§ÇÏ°Ô ¹ÌÄ¥ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

Á¶»ê¾Æ Áõ°¡´Â ÇâÈÄ ¼ö³â°£ ¼Ò¾Æ¿ë ÀǾàǰ ½ÃÀå ¼ºÀåÀ» À̲ø °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Á¶»êÀ̶õ ÀϹÝÀûÀÎ ÀӽŠ40ÁÖº¸´Ù ºü¸¥ ÀӽŠ37ÁÖ¸¦ ¸ÂÀÌÇϱâ Àü¿¡ ž À¯¾ÆÀÔ´Ï´Ù. Á¶»ê Áõ°¡¿¡´Â ¾î¸Ó´ÏÀÇ ³ªÀÌ »ó½Â, ¶óÀÌÇÁ ½ºÅ¸ÀÏ ¼±ÅÃ, º´¸®ÇÐ, ´ÙÅ ÀÓ½Å, ºÒÃæºÐ ÇÑ ÀÓ»êºÎ °ü¸® µî ¿©·¯ ¿äÀÎÀÌ ÀÖ½À´Ï´Ù. ¼Ò¾Æ¿ë ÀǾàǰÀº È£Èí±â ÇÕº´Áõ, °¨¿°Áõ, ¿µ¾ç ºÎÁ· µîÀÇ °úÁ¦¿¡ ÀÓÇÔÀ¸·Î½á Á¶»ê¾ÆÀÇ °Ç°­°ú °³¹ßÀ» Áö¿øÇϴµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 12¿ù ¿µ±¹À» ±â¹ÝÀ¸·Î ÇÑ ÀÚ¼± ´Üü Tommy's°¡ ¹ßÇ¥ÇÑ º¸°í¼­¿¡ µû¸£¸é ¿µ±¹°ú ¿þÀϽºÀÇ Á¶»ê¾Æ ºñÀ²Àº 2021³â 7.5%¿¡¼­ 2022³â 7.9%·Î Áõ°¡Çß½À´Ï´Ù. ÀÌ »ó½ÂÀ¸·Î 2022³â Á¶»êÀ¸·Î ž ¾Æ±â´Â 5¸¸ 3,000¸íÀ» ³Ñ¾î¼¹½À´Ï´Ù. ±× °á°ú, Á¶»ê¾Æ Áõ°¡°¡ ¼Ò¾Æ¿ë ÀǾàǰ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå : ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ¹«¿ªÀüÀï°ú °ü¼¼, ±×¸®°í Äڷγª ¹× ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹®, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Pediatric drugs are medications specifically formulated, dosed, and approved for use in infants, children, and adolescents. These drugs are designed to treat a wide range of medical conditions in pediatric patients, taking into account their unique physiological and metabolic differences from adults.

The primary types of pediatric drugs include respiratory disorder drugs, autoimmune disorder drugs, gastrointestinal drugs, and cardiovascular drugs. Respiratory disorder drugs are formulated to manage breathing-related conditions in children, such as asthma, cystic fibrosis, and respiratory syncytial virus (RSV). These medications can be administered through various routes, including oral, topical, and parenteral methods. They are distributed through multiple channels, such as hospital pharmacies, retail pharmacies, and online pharmacies. Pediatric drugs are utilized by various end users, including hospitals, specialty clinics, homecare settings, and other healthcare facilities.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The pediatric drugs market research report is one of a series of new reports from The Business Research Company that provides pediatric drugs market statistics, including the pediatric drugs industry global market size, regional shares, competitors with the pediatric drugs market share, detailed pediatric drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the pediatric drugs industry. This pediatric drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pediatric drugs market size has grown rapidly in recent years. It will grow from $157 billion in 2024 to $179.43 billion in 2025 at a compound annual growth rate (CAGR) of 14.3%. The growth in the historic period can be attributed to demand for related medications, demand with high pediatric population, increased pediatric disease awareness, expansion of pediatric oncology, rise of digital health and telemedicine, and increased collaboration in pediatric drug development.

The pediatric drugs market size is expected to see rapid growth in the next few years. It will grow to $308.57 billion in 2029 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to increasing pediatric population, rising prevalence of pediatric mental health issues, rising number of children with chronic conditions, higher vaccination rate in children and rising demand for pediatric mental health medications. Major trends in the forecast period include personalized pediatric medicine, technological integration in pediatric drug delivery, telemedicine and digital health solutions, enhance pediatric clinical trials, and collaboration between pediatricians and pharmacists.

The forecast of 14.5% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. children's hospitals by inflating prices of specialized pediatric formulations manufactured in Sweden and the Netherlands, resulting in delayed treatment for chronic childhood conditions and raising pediatric care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing number of preterm births is anticipated to drive the growth of the pediatric drugs market in the coming years. Preterm births refer to infants born before completing 37 weeks of gestation, which is earlier than the typical 40-week term. Several factors contribute to the rise in preterm births, including increased maternal age, lifestyle choices, medical conditions, multiple pregnancies, and inadequate prenatal care. Pediatric drugs play a crucial role in supporting the health and development of preterm infants by addressing challenges such as respiratory complications, infections, and nutritional deficiencies. For example, in December 2022, a report published by Tommy's, a UK-based charity organization, indicated that the percentage of premature live births in England and Wales increased to 7.9% in 2022, up from 7.5% in 2021. This rise accounted for more than 53,000 babies born prematurely in 2022. As a result, the growing number of preterm births is fueling the expansion of the pediatric drugs market.

Leading companies in the pediatric drugs market are focusing on developing innovative treatments, such as fully human monoclonal antibodies, to enhance therapeutic outcomes and reduce side effects for young patients. A fully human monoclonal antibody (mAb) is derived entirely from human genetic sequences, minimizing the risk of immune reactions compared to chimeric or humanized monoclonal antibodies. These antibodies are produced using advanced biotechnological techniques, such as transgenic mice with human antibody genes or phage display technology. For instance, in August 2022, Johnson & Johnson, a US-based pharmaceutical company, received FDA approval for STELARA (ustekinumab) to treat pediatric patients aged six years and older with active psoriatic arthritis (PsA). This approval marked a significant breakthrough, as STELARA is the first and only biologic therapy targeting interleukin-12 (IL-12) and interleukin-23 (IL-23), cytokines that play a key role in the inflammatory responses associated with autoimmune diseases. Active PsA is a rare condition that affects approximately 5-8% of children with chronic inflammatory arthritis, causing symptoms such as joint swelling and skin lesions.

In July 2022, JB Chemicals & Pharma Limited, an India-based pharmaceutical company, acquired four pediatric brands from Dr. Reddy's Laboratories for ₹98.3 crore (approximately $1.18 million). This acquisition was aimed at expanding JB Pharma's presence in the pediatric segment by leveraging the market leadership of the acquired brands to strengthen its portfolio and support future growth ambitions in India. Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company specializing in pediatric drug development.

Major players in the pediatric drugs market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb, AstraZeneca Plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Eli Lilly and Co., Gilead Sciences Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Vertex Pharmaceuticals, UCB Pharma, Sun Pharmaceutical Industries Ltd., Perrigo Company, Shionogi & Co. Ltd., Mallinckrodt, Torrent Pharmaceuticals Ltd, Sarepta Therapeutics, Zydus Cadila.

North America was the largest region in the pediatric drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pediatric drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pediatric drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pediatric drugs market consists of sales of antibiotics, vaccines, pediatric pain relief, respiratory medications, antihistamines, and pediatric dermatology products. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pediatric Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pediatric drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for pediatric drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pediatric drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Pediatric Drugs Market Characteristics

3. Pediatric Drugs Market Trends And Strategies

4. Pediatric Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Pediatric Drugs Growth Analysis And Strategic Analysis Framework

6. Pediatric Drugs Market Segmentation

7. Pediatric Drugs Market Regional And Country Analysis

8. Asia-Pacific Pediatric Drugs Market

9. China Pediatric Drugs Market

10. India Pediatric Drugs Market

11. Japan Pediatric Drugs Market

12. Australia Pediatric Drugs Market

13. Indonesia Pediatric Drugs Market

14. South Korea Pediatric Drugs Market

15. Western Europe Pediatric Drugs Market

16. UK Pediatric Drugs Market

17. Germany Pediatric Drugs Market

18. France Pediatric Drugs Market

19. Italy Pediatric Drugs Market

20. Spain Pediatric Drugs Market

21. Eastern Europe Pediatric Drugs Market

22. Russia Pediatric Drugs Market

23. North America Pediatric Drugs Market

24. USA Pediatric Drugs Market

25. Canada Pediatric Drugs Market

26. South America Pediatric Drugs Market

27. Brazil Pediatric Drugs Market

28. Middle East Pediatric Drugs Market

29. Africa Pediatric Drugs Market

30. Pediatric Drugs Market Competitive Landscape And Company Profiles

31. Pediatric Drugs Market Other Major And Innovative Companies

32. Global Pediatric Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pediatric Drugs Market

34. Recent Developments In The Pediatric Drugs Market

35. Pediatric Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â